Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10697836 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL9662549 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL10705645 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL3155982 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL359901 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL9662113 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL360518 | 0.98 | NAAA (1.00) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL3148607 | 0.95 | NAAA (0.88) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL15820610 | 0.90 | NAAA (0.84) | NAAATSHRHTTHPGDALDH1A1 | |
| SCHEMBL15820606 | 0.90 | NAAA (0.84) | NAAATSHRHTTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109369556-A | A kind of synthetic method of 5-N, N- dibenzylamine ethrisin | 格斯雅汇(天津)有限公司 | 2019-02-22 | — | — | CN | claimed |
| CN-118359514-A | N-ester salicylamide compound and preparation method and application thereof | 湖南科技大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-118164871-A | N-ester-2-acetylsalicylamide compound and preparation method and application thereof | 湖南科技大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| CN-104513177-B | A kind of preparation method of 5-(N, N-dibenzyl amino) ethrisin | 上海应用技术学院 | 2017-01-04 | — | — | CN | disclosed |
| EP-1578757-B1 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2014-10-22 | — | — | EP | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2483254-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8778939-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1578757-A2 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | Tibotec BVBA (BE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004058787-A2 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | TIBOTEC BVBA (BE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | NAAA 1790/4885TSHR 4051/4885HTT 3795/4885 |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | GLA, CHAT, MAPT | NAAA 318/4885TSHR 3997/4885HTT 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.